Sarepta Therapeutics Inc (SRPT) : Mason Capital Management added new position in Sarepta Therapeutics Inc during the most recent quarter end. The investment management firm now holds 175,000 shares of Sarepta Therapeutics Inc which is valued at $4,420,500 , the company said in a statement filed on Aug 15, 2016 with the SEC.Sarepta Therapeutics Inc makes up approximately 0.27% of Mason Capital Management’s portfolio.
Other Hedge Funds, Including , Point72 Asset Management boosted its stake in SRPT in the latest quarter, The investment management firm added 586,531 additional shares and now holds a total of 2,962,231 shares of Sarepta Therapeutics Inc which is valued at $74,825,955. Sarepta Therapeutics Inc makes up approx 0.60% of Point72 Asset Management’s portfolio.Teachers Advisors Inc boosted its stake in SRPT in the latest quarter, The investment management firm added 4,847 additional shares and now holds a total of 120,752 shares of Sarepta Therapeutics Inc which is valued at $3,050,196. Sarepta Therapeutics Inc makes up approx 0.01% of Teachers Advisors Inc’s portfolio.Spot Trading L.l.c boosted its stake in SRPT in the latest quarter, The investment management firm added 33,326 additional shares and now holds a total of 35,744 shares of Sarepta Therapeutics Inc which is valued at $971,522. Sarepta Therapeutics Inc makes up approx 0.13% of Spot Trading L.l.c’s portfolio. Mizuho Securities Usa added SRPT to its portfolio by purchasing 174,400 company shares during the most recent quarter which is valued at $4,166,416. Sarepta Therapeutics Inc makes up approx 0.76% of Mizuho Securities Usa’s portfolio.
Sarepta Therapeutics Inc opened for trading at $25.89 and hit $26.63 on the upside on Thursday, eventually ending the session at $26.56, with a gain of 1.88% or 0.49 points. The heightened volatility saw the trading volume jump to 13,62,792 shares. Company has a market cap of $1,272 M.
On the company’s financial health, Sarepta Therapeutics Inc reported $-1.19 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $-1.21.Analysts expectations of $ .10.During the same quarter in the previous year, the company posted $-0.87 EPS.
Many Wall Street Analysts have commented on Sarepta Therapeutics Inc. Company shares were Reiterated by Needham on Jul 22, 2016 to “Buy”, Firm has raised the Price Target to $ 26 from a previous price target of $20 .Sarepta Therapeutics Inc was Upgraded by Piper Jaffray to ” Neutral” on Jun 9, 2016. Wedbush Upgraded Sarepta Therapeutics Inc on Jun 7, 2016 to ” Outperform”, Price Target of the shares are set at $36.
Sarepta Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of unique ribonucleic acid (RNA-targeted therapeutics for the treatment of rare infectious and other diseases. The Company is primarily focused on advancing the development of its potentially disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates including its lead DMD product candidate eteplirsen which is an antisense PMO therapeutic in Phase III clinical development for the treatment of individuals with DMD who have an error in the gene coding for dystrophin that is amenable to skipping exon 51. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious rare and other human diseases.